Company intelligence / Profile preview
Electra Therapeutics
South San Francisco, California, United Stateselectra-therapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
ELA026 shows clinical activity in Phase1b trials for malignancy-associated HLH, with recent FDA Fast Track designation (2024) and upcoming ASH presentation of frontline treatment data[5][6].
- Therapeutic areas
- HematologyImmunologyOncology
- Modalities
- Monoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Electra Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Electra Therapeutics.